莫沙必利联合雷贝拉唑钠肠溶片治疗老年性反流性食管炎疗效评价
Assessment of clinical efficacy of mosapride combined with rabeprazole sodium enteric-coated tablet in the treatment of senile reflux esophagitis
-
摘要: 目的:探讨莫沙必利联合雷贝拉唑钠肠溶片治疗老年性反流性食管炎(RE)疗效。方法:选取我院收治的78例老年RE病人,随机分成对照组与观察组,每组39例。对照组予雷贝拉唑钠肠溶片每次20 mg,1次/天口服,观察组在此基础上再予莫沙必利每次5 mg,3次/天口服,均连续治疗8周。检测血浆胃肠激素[胃泌素(GAS)、胃动素(MTL)、血管活性肠肽(VIP)]及血清细胞因子水平[白细胞介素(IL)-6、IL-8及肿瘤坏死因子(TNF)-α],测定24 h食管pH值,评定典型RE症状评分,比较临床疗效。结果:与治疗前比较,2组血浆GAS、MTL升高(P<0.01),VIP降低(P<0.01),血清IL-6、IL-8、TNF-α降低(P<0.01),pH值<4反流次数、反流持续时间≥5min反流次数、最长反流持续时间、pH值<4总时间、pH值<4时间百分比降低(P<0.01),烧心、反酸、胸骨后灼痛典型RE症状评分降低(P<0.01);与对照组比较,观察组GAS、MTL较高(P<0.01),VIP较低(P<0.01),IL-6、IL-8、TNF-α较低(P<0.01),pH值<4反流次数、反流持续时间≥5 min反流次数、最长反流持续时间、pH值<4总时间、pH值<4时间百分比较低(P<0.01),烧心、反酸、胸骨后灼痛典型RE症状评分较低(P<0.01),总有效率较高(P<0.05)。结论:莫沙必利联合雷贝拉唑钠肠溶片治疗老年RE效果满意,与调控MTL及IL-6、TNF-α等因子有关。Abstract: Objective: To investigate the clinical effects of mosapride combined with rabeprazole sodium enteric-coated tablet in the treatment of senile reflux esophagitis(RE). Methods: Seventy-eight elderly patients with RE were randomly divided into the control group and observation group(39 cases each group).The control group was treated with 20 mg of rabeprazole sodium enteric-coated tablet each time,one tablet a day,and the observation group was treated with 5 mg of mosapride each time,3 times a day,based on the control group for 8 weeks.The serum levels of gastrointestinal hormones[gastrin(GAS),motilin(MTL) and vasoactive intestinal peptide(VIP)] and cytokines,and 24 h pH value of esophagus were measured,and the score of typical RE symptom was evaluated.The clinical effect between two groups was compared. Results: Compared with before treatment,the serum levels of GAS and MTL in two groups increased (P<0.01),and the serum levels of VIP,IL-6,IL-8 and TNF-α in two groups decreased after treatment(P<0.01).Compared with before treatment,the number of reflux(pH<4),reflux frequency(reflux duration ≥ 5 min),longest reflux duration time(pH<4),total time(pH<4)and percentage of time(pH<4) in two groups decreased after treatment(P<0.01).Compared with before treatment,the scores of the typical RE symptoms(heartburn,acid reflux and retrosternal burning pain) in two groups decreased after treatment(P<0.01).Compared with the control group,the levels of MTL and GAS in observation group were higher(P<0.01),the levels of VIP,IL-6,IL-8 and TNF-α in observation group were lower(P<0.01).Compared with the control group,the number of reflux(pH<4) and reflux frequency(reflux duration ≥ 5 min),longest reflux duration time(pH<4),total time(pH<4)and percentage of time(pH<4) in observation group were lower(P<0.01).Compared with the control group,the scores of the typical RE symptoms(heartburn,acid reflux,substernal burning pain) in observation group were lower(P<0.01),and the total effective rate in observation group was higher(P<0.05). Conclusions: The clinical effect of mosapride combined with rabeprazole sodium enteric-coated tablet in the treatment of senile RE is good,which may be associated with the regulation of factrs such as MTL,IL-6, TNF-α and so on.
-
Key words:
- reflux esophagitis /
- mosapride /
- rabeprazole sodium enteric-coated tablet /
- motilin
-
[1] 林晓冬,韩娟,程艳玲.反流性食管炎的研究进展——模型构建与发病机制[J].医学综述,2015,21(11):2022. [2] 尹宏伟,周慧芬.达力通颗粒联合泮托拉唑治疗老年反流性食管炎病人的临床效果[J].中华中医药学刊,2014,32(4):929. [3] 张林,邓晓玲,江艳燕,等.埃索美拉唑联合莫沙比利干预老年性反流性食管炎临床研究[J].现代生物医学进展,2014,14(2):320. [4] 田晶晶,胡蓆宝,袁红霞.中医药治疗反流性食管炎实验研究进展[J].云南中医中药杂志,2015,36(9):70. [5] 杨芸峰,浦斌红,屠丽萍,等.反流性食管炎的临床治疗研究进展[J].西部中医药,2015,28(5):146. [6] 陆星华,张泰昌.反流性食管炎诊断及治疗指南(2003年)[J].中华消化内镜杂志,2004,21(4):221. [7] 冯子南,尹广利,徐湘江,等.雷贝拉唑联合莫沙比利治疗反流性食管炎的临床观察[J].中国医药导刊,2015,17(3):278. [8] 李春艳,孟华,郭世斌,等.老年反流性食管炎临床特征分析[J].中华实用诊断与治疗杂志,2012,26(10):1030. [9] 祁小鸣,陈恕之,周步良,等.老年人反流性食管炎临床特点分析[J].胃肠病学和肝病学杂志,2012,21(10):933. [10] 邹小平,莫红.探讨老年人反流性食管炎的临床特点[J].检验医学与临床,2015,12(13):1862. [11] SZCZESNIAK MM,FUENTEALBA SE,COOK IJ.Acid sensitization of esophageal mucosal afferents:implication for symptom perception in patients across the gastroesophageal reflux disease spectrum[J].Clin J Pain,2013,29(1):70. [12] 王瀛峰,张继全,吴飞,等.胃食管反流病的中西医发病机制及临床治疗的研究进展[J].世界华人消化杂志,2013,21(34):3821. [13] 赵世民,杨彩丰,高春燕,等.雷贝拉唑联合四逆散治疗反流性食管炎的疗效及对血清胃泌素、血浆胃动素水平的影响[J].现代中西医结合杂志,2016,25(19):2093. [14] 吴晖,陈朝元,何顺勇.疏降饮对肝胃不和型反流性食管炎的血VIP、MTL的影响[J].浙江中医药大学学报,2011,35(4):498. [15] 田燕,陈吉.炎症介质与胃食管反流病发病机制的研究进展[J].疾病监测与控制,2016,10(1):34. [16] 袁红霞,史业骞,刘清君,等.旋覆代赭汤对反流性食管炎模型大鼠IL-6及TNF-α的影响[J].辽宁中医杂志,2012(1):3. [17] 张萌,黄刚,周志刚,等.奥美拉唑对大鼠反流性食管黏膜损伤后IL-6及TNF-α的影响[J].河北医学,2015,21(11):1768. [18] 李笑梅.解郁清胃汤治疗肝胃郁热型反流性食管炎作用机制研究[J].四川中医,2016,34(11):85. [19] 李菁,李荣东.质子泵抑制剂的研究进展[J].儿科药学杂志,2014,20(4):126. [20] 王文波.雷贝拉唑与奥美拉唑治疗老年反流性食管炎的内镜疗效对比[J].海南医学院学报,2014,20(12):1644. [21] 胡毅,丁玲,刁攀娅,等.比较雷贝拉唑与奥美拉唑治疗反流性食管炎的临床效果[J].中国中西医结合消化杂志,2014,22(6):322. [22] 詹广场,蒋成佳.埃索美拉唑联合枸橼酸莫沙必利治疗反流性食管炎的效果观察[J].中国医药,2014,9(6):820. [23] 黄丹雅,汪洋.兰索拉唑片联合莫沙必利分散片治疗反流性食管炎34例[J].中国药师,2014,17(1):110. [24] 赖新兰,杨新魁,刘水清,等.莫沙必利联合雷贝拉唑钠治疗反流性食管炎的临床研究[J].现代药物与临床,2016,31(10):1538.
计量
- 文章访问数: 7695
- HTML全文浏览量: 670
- PDF下载量: 89
- 被引次数: 0